STEVE ELMS - 23 Dec 2024 Form 4 Insider Report for Marker Therapeutics, Inc. (MRKR)

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRKR	Common Stock	Purchase	$35,472	+11,085	+3.5%	$3.2	325,370	23 Dec 2024	See Footnote	F1, F2, F3
holding	MRKR	Common Stock						2,968	23 Dec 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	On January 26, 2023, the Issuer effected a 1-for-10 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.
F2	Acquired from the Issuer on December 23, 2024 pursuant to a Securities Purchase Agreement dated December 19, 2024.
F3	The reportable securities are directly owned by Aisling Capital IV, LP ("Aisling"), and which may be deemed to be beneficially owned by Aisling Capital Partners IV, LP ("Aisling GP"), as general partner of Aisling, Aisling Capital Partners IV LLC ("Aisling Partners"), as general partner of Aisling GP, and each of the individual managing members and partners (collectively, the "Managers") of Aisling GP and Aisling Partners. The Managers of Aisling Partners are Dr. Andrew Schiff and Steve Elms, who have shared voting and dispositive power over the shares. Mr. Elms, the Reporting Person, disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, and the inclusion of these securities herein shall not be deemed an admission of beneficial ownership for purposes of Section 16 or for any other purpose.